Open AccessE‐cadherin expression is associated with somatostatin analogue response in acromegaly
Author(s) -
VenegasMoreno Eva,
FloresMartinez Alvaro,
Dios Elena,
VazquezBorrego Mari C.,
IbañezCosta Alejandro,
MadrazoAtutxa Ainara,
Japón Miguel A.,
Castaño Justo P.,
Luque Raúl M.,
Cano David A.,
SotoMoreno Alfonso
Publication year - 2019
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13851
Subject(s) - acromegaly , somatostatin , medicine , immunohistochemistry , endocrinology , octreotide , pathology , oncology , hormone , growth hormone
Acromegaly is a rare disease resulting from hypersecretion of growth hormone ( GH ) and insulin‐like growth factor 1 ( IGF 1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues ( SSA s) represent the primary medical therapy for acromegaly and are currently used as first‐line treatment or as second‐line therapy after unsuccessful pituitary surgery. However, a considerable proportion of patients do not adequately respond to SSA s treatment, and therefore, there is an urgent need to identify biomarkers predictors of response to SSA s. The aim of this study was to examine E‐cadherin expression by immunohistochemistry in fifty‐five GH ‐producing pituitary tumours and determine the potential association with response to SSA s as well as other clinical and histopathological features. Acromegaly patients with tumours expressing low E‐cadherin levels exhibit a worse response to SSA s. E‐cadherin levels are associated with GH ‐producing tumour histological subtypes. Our results indicate that the immunohistochemical detection of E‐cadherin might be useful in categorizing acromegaly patients based on the response to SSA s.